GSK plc 6-K, filed Feb 17, 2022
GSK plc (GSK)
6-K
2022-02-17
For: 2022-02-17
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on February 17, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company' and 'GSK')
Vesting of Awards under the GSK Deferred Investment Award
programme
This notification sets out the vesting details for Persons
Discharging Managerial Responsibilities ('PDMRs') of awards made in
2019 to under the GlaxoSmithKline Deferred Investment Award
programme (the 'Programme'). The awards, which were conditional on
continued employment with the GlaxoSmithKline group, vested on 14
February 2022.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms D Conrad
|
|||
|
b)
|
Position/status
|
Chief People Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
Following the vesting on 14 February 2022 of an award made on 3
September 2019 under the GlaxoSmithKline Deferred Investment Award
programme, Ms Conrad will receive a cash payment of
£157,905.60 less applicable tax withholding in respect of
10,050 notional ordinary shares.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.712
|
10,050
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-14
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Jackson
|
|||
|
b)
|
Position/status
|
SVP, Global Communication and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
Following the vesting on 14 February 2022 of an award made on 3
September 2019 under the GlaxoSmithKline Deferred Investment Award
programme, Ms Jackson will receive a cash payment of
£157,905.60 less applicable tax withholding in respect of
10,050 notional ordinary shares.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.712
|
10,050
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2022-02-14
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
17, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|